News

​A drug candidate has been found in preclinical trials to stop tumor growth entirely, deliver more cancer-busting power than many commonly used chemotherapy drugs and do so with fewer toxic side effects and more ability to overcome resistance.

Researchers from The University of Texas at Austin and the National Institutes of Health have made a critical breakthrough toward developing a vaccine for the 2019 novel coronavirus by creating the first 3D atomic scale map of the part of the virus that attaches to and infects human cells.

A widely used class of chemotherapy drugs, called topoisomerase inhibitors, come with some serious downsides: bone marrow damage, reduced blood cell production, diarrhea and heart damage. And some cancers can quickly develop resistance. A new discovery about a second class of drugs might lead to combination therapies that are just as effective, but with fewer downsides.

New faculty in Natural Sciences conduct compelling research and inspire new generations, right out of the gate. As the 2019-20 academic year begins, we are introducing faculty members whose compelling work is worth learning about. Here meet Kami Hull. Within months of joining the faculty, she won a prestigious Novartis Early Career Award in Chemistry in recognition of her research, which involves developing more efficient processes for synthetic organic chemistry.

Traumatic brain injuries (TBIs), caused by everything from falls to being hit by moving objects to car crashes, cause nearly a third of all injury-related deaths in the U.S. Millions of survivors struggle with impaired thinking and movement, personality changes or depression.

Until now, researchers haven't been able to accurately quantify a latent form of HIV that persists in patients' immune cells. This hampers doctors' ability to assess the effectiveness of a particular treatment and select better alternatives.

A foundation that has set a goal this decade of identifying 50 inventors who will shape the next 50 years has added its second University of Texas at Austin faculty member to the list. The Gordon and Betty Moore Foundation announced Livia Eberlin, assistant professor in the Department of Chemistry, is one of this year's five Moore Inventor fellows.

Last year, Texas saw a particularly deadly flu season. Now, there is a new Federal Drug Administration-approved treatment, Xofluza, designed to catch the flu in its early stages and stop it from spreading. The drug is thanks in large part to professor emeritus Robert Krug's basic research, undertaken almost 40 years ago.

A team of researchers at The University of Texas at Austin has demonstrated a new way to sequence proteins that is much more sensitive than existing technology, identifying individual protein molecules rather than requiring millions of molecules at a time. The advance could have a major impact in biomedical research, making it easier to reveal new biomarkers for the diagnosis of cancer and other diseases, as well as enhance our understanding of how healthy cells function.

Updated on August 31, 2018: This release was updated to correct mistakes in descriptions of the way cancer cells develop drug resistance and the way that anti-cancer drug DCA affects the metabolism of cancer cells.

A new drug lead shows promise that it could reduce the size of cancerous tumors much more effectively than current treatments.